Jianing Wang
Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia
BackgroundCombination therapy with programmed death-1 (PD-1) inhibitors and targeted therapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). Patients with hyperbilirubinemia (total bilirubin > upper limit of normal) are often exc…